Bortezomib-based regimens are beneficial in the treatment of patients with symptomatic, newly diagnosed and relapsed or refractory multiple myeloma. Researchers who investigated the efficacy and safety of single-agent bortezomib as first-line therapy in patients with myeloma have particularly emphasized the incidence and management of peripheral neuropathy, which is the most common adverse effect of bortezomib administration.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
Scientific Reports Open Access 30 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487–2498 (2005).
Terpos, E. et al. Bortezomib in multiple myeloma. Expert Opin. Drug Metab. Toxicol. 4, 639–654 (2008).
San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906–917 (2008).
Pineda-Roman, M. et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br. J. Hematol. 140, 625–634 (2008).
Richardson, P. G. et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27, 3518–3525 (2009).
Harousseau, J. L. et al. Bortezomib plus dexamethasone as induction treatment before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Hematologica 91, 1498–1505 (2006).
Harousseau, J. L. et al. Bortezomib/dexamethasone versus VAD as induction before autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J. Clin. Oncol. 26 (Suppl.), 8505 (2008).
Cavo, M. et al. Bortezomib (Velcade)–thalidomide–dexamethasone (VTD) vs thalidomide–dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) [Abstract 73]. Blood 110 (Suppl.), 30a (2007).
England, J. D. et al. Distal symmetric polyneuropathy: a definition for clinical research. Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64, 199–207 (2005).
Hulin, C. et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 27, 3664–3670 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. A. Dimopoulos and E. Terpos declare that they are on the speakers' bureau and receive grant/research support from Janssen-Cilag.
Rights and permissions
About this article
Cite this article
Dimopoulos, M., Terpos, E. First-line bortezomib benefits patients with multiple myeloma. Nat Rev Clin Oncol 6, 683–685 (2009). https://doi.org/10.1038/nrclinonc.2009.171
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.171
This article is cited by
-
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Cancer Gene Therapy (2022)
-
The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
Scientific Reports (2016)
